Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00294372
Recruitment Status : Terminated
First Posted : February 22, 2006
Last Update Posted : November 14, 2013
Information provided by:
Boehringer Ingelheim

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : September 2007
  Study Completion Date : No date given